Insider Trading disclosures for Lyra Therapeutics Inc

The latest disclosure was made by Maria Palasis in Lyra Therapeutics Inc where a trade of 183,333 Employee Stock Option (right to buy) done was reported to US exchanges on Dec. 9, 2024.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Show

Client Name	Client Category	Action	Reported to Exchange	Quantity	Post Transaction Holding	Traded %	Avg. Price	Value	Security Type
Maria Palasis	Director, President & CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	09 Dec 2024	183,333	183,333	-		-	Employee Stock Option (right to buy)
Harlan W. Waksal	Director, Executive Chair	Grant, award, or other acquisition of securities at price $ 0.00 per share.	09 Dec 2024	128,333	0	-		-	Performance-based Restricted Stock Units
Jason Cavalier	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	16 Oct 2024	100,000	100,000	-		0	Common Stock
Maria Palasis	Director, President & CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	16 Oct 2024	300,000	300,000	-		0	Common Stock
C. Ann Merrifield	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	13 Jun 2024	30,000	30,000	-		-	Stock Option
James R. Tobin	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	13 Jun 2024	30,000	30,000	-		-	Stock Option
W. Bradford Smith	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	13 Jun 2024	30,000	30,000	-		-	Stock Option
Nancy L. Snyderman	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	13 Jun 2024	30,000	30,000	-		-	Stock Option
Konstantin Poukalov	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	13 Jun 2024	30,000	30,000	-		-	Stock Option
Michael Altman	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	13 Jun 2024	30,000	30,000	-		-	Stock Option
Maria Palasis	Director, President & CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	18 Mar 2024	500,000	500,000	-		-	Stock Option
Harlan W. Waksal	Director, Executive Chair	Grant, award, or other acquisition of securities at price $ 0.00 per share.	18 Mar 2024	275,000	536,966	-		0	Common Stock
Bishop E. John	Chief Technology Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	30 Jan 2024	200,000	200,000	-		-	Stock Options
Jason Cavalier	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	30 Jan 2024	200,000	200,000	-		-	Stock Options
Nieman Richard	Chief Medical Officer		30 Jan 2024	200,000	200,000	-		-	Stock Options
C. Ann Merrifield	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	30 Jun 2023	20,000	20,000	-		-	Stock Option
James R. Tobin	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	30 Jun 2023	20,000	20,000	-		-	Stock Option
W. Bradford Smith	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	30 Jun 2023	20,000	20,000	-		-	Stock Option
Nancy L. Snyderman	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	30 Jun 2023	20,000	20,000	-		-	Stock Option
Konstantin Poukalov	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	30 Jun 2023	20,000	20,000	-		-	Stock Option
Michael Altman	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	30 Jun 2023	20,000	20,000	-		-	Stock Option
Maria Palasis	Director, President & CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	15 Jun 2023	150,000	150,000	-		-	Stock Option
John E. Bishop	Chief Technology Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	27 Feb 2023	220,000	220,000	-		-	Stock Option
Maria Palasis	Director, President & CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2023	250,000	250,000	-		-	Stock Option
Richard Nieman	Chief Medical Officer		31 Jan 2023	55,537	55,537	-		-	Stock Option
Jason Cavalier	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2023	140,000	140,000	-		-	Stock Option
Robert E. Richard	SVP, Technical Operations	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2023	30,000	30,000	-		0	Common Stock
Robert E. Richard	SVP, Technical Operations	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2023	45,000	45,000	-		-	Stock Option
Corinne Noyes	See Remarks	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2023	36,667	36,667	-		0	Common Stock
Harlan W. Waksal	Director, Executive Chair	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2023	200,000	200,000	-		-	Stock Option
Corinne Noyes	See Remarks	Grant, award, or other acquisition of securities at price $ 0.00 per share.	31 Jan 2023	55,000	55,000	-		-	Stock Option
Richard Nieman	Chief Medical Officer		11 Jul 2022	230,000	230,000	-		-	Stock Option
C. Ann Merrifield	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	16 Jun 2022	7,250	7,250	-		-	Stock Option
Harlan W. Waksal	Director, Executive Chair	Grant, award, or other acquisition of securities at price $ 0.00 per share.	16 Jun 2022	953,002	953,002	-		-	Stock Option
W. Bradford Smith	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	16 Jun 2022	7,250	7,250	-		-	Stock Option
Nancy L. Snyderman	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	16 Jun 2022	7,250	7,250	-		-	Stock Option
Konstantin Poukalov	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	16 Jun 2022	7,250	7,250	-		-	Stock Option
Michael Altman	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	16 Jun 2022	7,250	7,250	-		-	Stock Option
C. Ann Merrifield	Director	Purchase of securities on an exchange or from another person at price $ 5.05 per share.	10 Jun 2022	4,000	11,328	-	5.1	20,200	Common Stock
C. Ann Merrifield	Director	Purchase of securities on an exchange or from another person at price $ 5.00 per share.	13 May 2022	328	7,328	-	5	1,640	Common Stock
C. Ann Merrifield	Director	Purchase of securities on an exchange or from another person at price $ 4.81 per share.	13 May 2022	3,500	7,000	-	4.8	16,846	Common Stock
Harlan W. Waksal	Director, Executive Chair	Purchase of securities on an exchange or from another person at price $ 4.22 per share.	12 Apr 2022	236,966	236,966	-	4.2	999,997	Common Stock
James R. Tobin	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	04 Mar 2022	14,500	14,500	-		-	Stock Option
Harlan W. Waksal	Director, Executive Chair	Grant, award, or other acquisition of securities at price $ 0.00 per share.	16 Feb 2022	520,000	520,000	-		-	Stock Option
Maria Palasis	Director, President & CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	16 Feb 2022	175,000	175,000	-		-	Stock Option
Maria Palasis	Director, President & CEO	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Feb 2022	127,400	127,400	-		-	Stock Option
Corinne Noyes	See Remarks	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Feb 2022	32,000	32,000	-		-	Stock Option
Robert E. Richard	SVP, Technical Operations	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Feb 2022	35,000	35,000	-		-	Stock Option
Pamela E. Nelson	SVP, Regulatory Affairs	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Feb 2022	30,000	30,000	-		-	Stock Option
Jason Cavalier	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	12 Feb 2022	15,605	15,605	-		-	Stock Option

Showing 1 to 50 of 81 entries

*All Values are in $ Million

Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures

Data as reported to USA Exchanges

View All The Insider Trades disclosures

New 52W Low today

Insider Trading disclosures for Lyra Therapeutics Inc

The latest disclosure was made by Maria Palasis in Lyra Therapeutics Inc where a trade of 183,333 Employee Stock Option (right to buy) done was reported to US exchanges on Dec. 9, 2024.

Screeners based on Insider Trading and SAST parameters